Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant state for a spectrum of lymphoplasmacytic malignancies. The risk of progression of MGUS to a symptomatic therapy requiring plasma cell dyscrasia is about 1% per year. Studies carried out over the previous 10 years have improved risk stratification of MGUS based on serologic and genomic evaluations, which has led to better management of patients. In this review, we address the epidemiology, diagnosis, and pathogenesis of MGUS and discuss risk-adapted best practice approaches to monitor patients.
Keyphrases
- risk assessment
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- primary care
- multiple myeloma
- single cell
- prognostic factors
- risk factors
- gene expression
- quality improvement
- patient reported outcomes
- copy number
- coronavirus disease
- mesenchymal stem cells
- respiratory syndrome coronavirus